Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 169
Filtrar
Más filtros

Medicinas Complementárias
Tipo del documento
Intervalo de año de publicación
1.
J Pharmacol Sci ; 143(1): 45-51, 2020 May.
Artículo en Inglés | MEDLINE | ID: mdl-32169433

RESUMEN

The leaves of Lindera aggregate (Sims) Kosterm. are traditionally used as healthy tea for the prevention and treatment of hyperlipidemia in Chinese. The aim of this study was to evaluate the antihyperlipidemic effects and potential mechanisms of the aqueous extracts from L. aggregate leaves (AqLA-L) on normal and hypercholesterolemic (HCL) mice. HCL mice were induced by high fat diet (HFD) and orally administrated with or without AqLA-L for ten days. The results showed that AqLA-L (0.3, 0.6, 1.2 g/kg) significantly reduced serum TG, ALT, but elevated fecal TG in normal mice. AqLA-L (0.3, 0.6, 1.2 g/kg) also remarkably lowered serum TC, TG, LDL, N-HDL, ALT, GLU, APOB, hepatic GLU and increased serum HDL, APOA-I, fecal TG levels in HCL mice. These results revealed that AqLA-L treatment regulated the disorders of the serum lipid and liver function, reduced hepatic GLU contents both in normal and HCL mice. The potential mechanisms for cholesterol-lowering effects of AqLA-L might be up-regulation of cholesterol 7-alpha-hydroxylase (CYP7A1) and ATP-binding cassette transporter A1 (ABCA1), as well as down-regulation of 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR). The data indicated that AqLA-L has potential therapeutic value in treatment of hyperlipidemia with great application security.


Asunto(s)
Hipercolesterolemia/sangre , Hipercolesterolemia/metabolismo , Lindera/química , Metabolismo de los Lípidos/efectos de los fármacos , Lípidos/sangre , Extractos Vegetales/farmacología , Hojas de la Planta/química , Transportador 1 de Casete de Unión a ATP/metabolismo , Administración Oral , Animales , Colesterol 7-alfa-Hidroxilasa/metabolismo , Hidroximetilglutaril-CoA Reductasas/metabolismo , Hipercolesterolemia/tratamiento farmacológico , Hipercolesterolemia/fisiopatología , Hígado/fisiopatología , Masculino , Ratones Endogámicos ICR , Fitoterapia , Extractos Vegetales/administración & dosificación , Regulación hacia Arriba/efectos de los fármacos , Agua
2.
Arch Oral Biol ; 109: 104553, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31563004

RESUMEN

This study evaluated the effects of replacing a saturated fat diet by n-3 polyunsaturated fatty acids (n-3PUFA), on alveolar bone loss in hypercholesterolemic rats with experimental periodontitis (PD). METHODS: Eight week old Wistar rats were assigned according to dietary intake. Control group (C, n = 15) fed a commercial diet throughout the experiment. Atherogenic group (AT, n = 30) fed AT diet for 3 weeks; thereafter, AT was randomized to receive either a n-3PUFA (n = 15) or to continue with AT (n = 15) diet. Subsequently, PD was induced in all groups by unilateral ligature (L) of the first molar (M1) of the left mandible, non-ligated contralateral molars served as controls. After every week of PD induction, 5 rats per group were euthanized. Serum was collected for lipids assays and hemi-mandibles were subjected to histomorphometric (% upper and lower interradicular bone volume and periodontal ligament height, hPDL) and radiographic analyses (periodontal bone support, PBS, in ligated teeth, between M1-M2). RESULTS: Rats fed n-3PUFA diet rapidly induced a significant reduction in the serum lipids (p < 0.001). In all rats the ligated teeth showed a greater bone loss as compared with the unligated molars. At the end of the experiment the AT + L was the worst in % lower bone volume (p < 0.01), hPDL and PBS (p < 0.05). In contrast, rats fed n-3PUFA + L was similar to those rats fed C diet (p > 0.05). CONCLUSION: Alveolar bone and dyslipidemia improved by substituting saturated fat intake for a n-3PUFA rich diet, in hypercholesterolemic rats with PD.


Asunto(s)
Pérdida de Hueso Alveolar/terapia , Dieta , Ácidos Grasos Omega-3/administración & dosificación , Aceites de Pescado/administración & dosificación , Hipercolesterolemia/fisiopatología , Periodontitis/fisiopatología , Animales , Dislipidemias/terapia , Distribución Aleatoria , Ratas , Ratas Wistar
3.
Int J Med Mushrooms ; 22(11): 1067-1078, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33426838

RESUMEN

Alzheimer's disease (AD) is the leading neurodegenerative disorder affecting memory and learning of aged people. Hypercholesterolemia had been implicated as one of the stark hallmarks of AD. Recent AD control guidelines have suggested lifestyle modification to slow down the progression of AD. In this regard, medicinal mushroom Ganoderma lucidum seems apt. In the present study, hot water extract of G. lucidum (200 mg/kg body weight) was fed to the hypercholesterolemic and AD model rats for 8 weeks. Nonspatial memory and learning abilities of the model animals was assessed using novel object recognition (NOR) test, rotarod test, and locomotor/open-field test. Then, the animals were sacrificed and transmission electron micrograph (TEM) view of the hippocampal neurons was assessed. In all the nonspatial memory and learning tests, the G. lucidum HWE fed rats performed better indicating improved memory and learning abilities. TEM view showed regular arrangement of the neurons in the G. lucidum HWE fed rats compared with those of the deranged arrangement of the AD rats. G. lucidum might have aided in restoring the memory and learning abilities of the AD model animals through maintaining neuronal structure and function. Thus, G. lucidum could be suggested as a medicotherapeutic agent against AD.


Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/psicología , Medicamentos Herbarios Chinos/administración & dosificación , Hipercolesterolemia/tratamiento farmacológico , Hipercolesterolemia/psicología , Enfermedad de Alzheimer/fisiopatología , Animales , Hipocampo/efectos de los fármacos , Hipocampo/fisiopatología , Humanos , Hipercolesterolemia/fisiopatología , Aprendizaje/efectos de los fármacos , Masculino , Memoria/efectos de los fármacos , Neuronas/efectos de los fármacos , Neuronas/fisiología , Ratas , Ratas Wistar , Reishi
4.
Nutrients ; 10(7)2018 Jun 28.
Artículo en Inglés | MEDLINE | ID: mdl-29958397

RESUMEN

Increasing evidence indicates that lean fish consumption may benefit cardiovascular health. High cholesterol and low n-3 PUFA concentrations in serum are associated with an increased risk of coronary heart disease; therefore, it is of interest to investigate effects of cod intake on cholesterol and n-3 PUFAs in serum and tissues. Hypercholesterolemic obese Zucker fa/fa rats were fed diets containing 25% protein from baked cod fillet and 75% protein from casein (Baked Cod Diet), or casein as the sole protein source (Control Diet) for four weeks. Consuming Baked Cod Diet resulted in lower serum cholesterol and lower hepatic mRNA concentrations of HMG-CoA reductase and sterol O-acyltransferase-2 without affecting serum bile acid concentration, faecal excretion of cholesterol and bile acid, and hepatic concentrations of bile acids, cholesterol and cholesterol 7 alpha-hydroxylase mRNA when compared to Control Diet. Rats fed Baked Cod Diet had higher concentrations of n-3 PUFAs in serum, liver, skeletal muscle and adipose tissue. To conclude, baked cod fillet intake resulted in lower serum cholesterol, which was probably caused by lower endogenous cholesterol synthesis, and higher n-3 PUFA in serum and tissues in obese Zucker fa/fa rats. These findings support the evidence that lean fish consumption might benefit cardiovascular health.


Asunto(s)
Alimentación Animal , Colesterol/sangre , Culinaria , Ácidos Grasos Omega-3/sangre , Gadiformes , Hipercolesterolemia/dietoterapia , Obesidad/dietoterapia , Alimentos Marinos , Tejido Adiposo Blanco/metabolismo , Fenómenos Fisiológicos Nutricionales de los Animales , Animales , Ácidos y Sales Biliares/sangre , Biomarcadores/sangre , Modelos Animales de Enfermedad , Heces/química , Regulación Enzimológica de la Expresión Génica , Calor , Hidroximetilglutaril-CoA Reductasas/genética , Hidroximetilglutaril-CoA Reductasas/metabolismo , Hipercolesterolemia/sangre , Hipercolesterolemia/genética , Hipercolesterolemia/fisiopatología , Hígado/metabolismo , Masculino , Músculo Esquelético/metabolismo , Estado Nutricional , Obesidad/sangre , Obesidad/genética , Obesidad/fisiopatología , ARN Mensajero/genética , ARN Mensajero/metabolismo , Ratas Zucker , Esterol O-Aciltransferasa/genética , Esterol O-Aciltransferasa/metabolismo , Esterol O-Aciltransferasa 2
5.
Arch Physiol Biochem ; 124(4): 313-325, 2018 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-29171301

RESUMEN

CONTEXT: Hypercholesterolemia has significant cardiac consequences, since it is among the major risk factors of ischemic heart diseases. OBJECTIVE: The aim was searching the cardioprotective effect of chemical constituents from the sea lettuce Ulva lactuca upon hypercholesterolemic regime in mice. MATERIAL AND METHODS: Mice were randomly divided into three groups: untreated group, hypercholesterolemic group, and mice receiving 1% cholesterol associated with U. lactuca ethanolic extract. RESULTS: In vitro study demonstrated that algal extract has antioxidant efficacy attributable to the presence of phenolic compounds. Additionally, the alga alleviated cardiotoxicity, as shown by the improvement of haematological parameters, white cell viability, heart oxidative stress, plasma biochemical parameters and index of atherogenesis. Gene expression of the proinflammatory cytokines TNF-α, IL-1ß and IL-6 significantly decreased in the heart of U. lactuca supplemented hypercholesterolemic animals. CONCLUSION: It was established that the green alga, thanks to its bioactive compounds, effectively counteracts cardiotoxic effects of hypercholesterolemic regime.


Asunto(s)
Anticolesterolemiantes/uso terapéutico , Productos Biológicos/uso terapéutico , Cardiotónicos/uso terapéutico , Suplementos Dietéticos , Hipercolesterolemia/prevención & control , Algas Marinas/química , Ulva/química , Animales , Anticolesterolemiantes/química , Antioxidantes/uso terapéutico , Aterosclerosis/etiología , Aterosclerosis/prevención & control , Biomarcadores/sangre , Biomarcadores/metabolismo , Cardiotónicos/química , Enfermedad Coronaria/etiología , Enfermedad Coronaria/prevención & control , Citocinas/genética , Citocinas/metabolismo , Suplementos Dietéticos/análisis , Etanol/química , Regulación de la Expresión Génica , Hipercolesterolemia/metabolismo , Hipercolesterolemia/patología , Hipercolesterolemia/fisiopatología , Ratones , Miocardio/inmunología , Miocardio/metabolismo , Miocardio/patología , Estrés Oxidativo , Distribución Aleatoria , Solventes/química
6.
Biomed Pharmacother ; 95: 944-955, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-28915536

RESUMEN

The potential protective role of the standardized leaf extract of ginkgo biloba (EGb761) on hypertension with hypercholesterolemia-induced renal injury was investigated in rats. Hypertension was induced by L-N(G)-nitroarginine methyl ester (L-NAME) and hypercholesterolemia was induced by feeding rats with a diet containing 1% cholesterol. In these animals repeated treatment with EGb761 produced a progressive reduction in the systolic, diastolic and mean arterial blood pressure (BP). EGb761 increased the progressive reduction in the systolic, diastolic and mean arterial BP induced by repeated administration of losartan with simvastatin. EGb761 corrected the compromised serum lipid profile and enhanced the effect of losartan with simvastatin on lipid profile. EGb761 protected against hypertension with hypercholesterolemia-induced renal injury as assessed by measurement of serum renal function markers and by histopathological examination. EGb761 enhanced the renoprotective effect of losartan with simvastatin in these rats. Concomitantly, hypertension with hypercholesterolemia-induced elevation of renal tissue malondialdehyde (MDA) and nitrite levels and reduction of intracellular reduced glutathione (GSH) level were inhibited by repeated treatment with EGb761. In addition, hypertension with hypercholesterolemia-induced increases in tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and interleukin-1ß (IL-1ß) levels in renal tissues were inhibited by treatment with EGb761. Also, EGb761 inhibited hypertension with hypercholesterolemia-induced decrease in endothelial nitric oxide synthase (eNOS) protein expression and increase in the protein expressions of inducible NO synthase (iNOS), TNF-α, IL-6 and IL-1ß in the kidney tissues. Losartan with simvastatin produced similar effects on renal tissues oxidative stress, nitrite and inflammatory markers levels and on protein expressions of eNOS, iNOS, TNF-α, IL-6 and IL-1ß. EGb761 enhanced losartan with simvastatin effects. These results indicate that EGb761 has the ability to protect against hypertension with hypercholesterolemia-induced renal injury. The ability of EGb761 to provide this renoprotective effect may positively correlate, besides its antihypertensive and antihypercholesterolemic effects, to its ability to suppress renal oxidative stress, nitrosative stress and inflammation.


Asunto(s)
Hipercolesterolemia/complicaciones , Hipercolesterolemia/tratamiento farmacológico , Hipertensión/complicaciones , Hipertensión/tratamiento farmacológico , Riñón/lesiones , Extractos Vegetales/uso terapéutico , Sustancias Protectoras/uso terapéutico , Animales , Presión Sanguínea/efectos de los fármacos , Creatinina/sangre , Diástole/efectos de los fármacos , Ginkgo biloba , Glutatión/metabolismo , Hipercolesterolemia/fisiopatología , Hipertensión/fisiopatología , Riñón/efectos de los fármacos , Riñón/patología , Riñón/fisiopatología , Lípidos/sangre , Losartán/farmacología , Losartán/uso terapéutico , Masculino , Malondialdehído/metabolismo , Óxido Nítrico Sintasa de Tipo III/metabolismo , Nitritos/metabolismo , Extractos Vegetales/administración & dosificación , Extractos Vegetales/farmacología , Sustancias Protectoras/farmacología , Ratas Wistar , Simvastatina/farmacología , Simvastatina/uso terapéutico , Sístole/efectos de los fármacos , Urea/sangre
7.
J Nutr Biochem ; 47: 29-34, 2017 09.
Artículo en Inglés | MEDLINE | ID: mdl-28501703

RESUMEN

Xanthohumol, a prominent prenyl flavonoid from the hop plant (Humulus lupulus L.), is suggested to be antiatherogenic since it reportedly increases high-density lipoprotein (HDL) cholesterol levels. It is not clear whether xanthohumol promotes reverse cholesterol transport (RCT), the most important antiatherogenic property of HDL; therefore, we investigated the effects of xanthohumol on macrophage-to-feces RCT using a hamster model as a CETP-expressing species. In vivo RCT experiments showed that xanthohumol significantly increased fecal appearance of the tracer derived from intraperitoneally injected [3H]-cholesterol-labeled macrophages. Ex vivo experiments were then employed to investigate the detailed mechanism by which xanthohumol enhanced RCT. Cholesterol efflux capacity from macrophages was 1.5-fold higher in xanthohumol-fed hamsters compared with the control group. In addition, protein expression and lecithin-cholesterol acyltransferase activity in the HDL fraction were significantly higher in xanthohumol-fed hamsters compared with the control, suggesting that xanthohumol promoted HDL maturation. Hepatic transcript analysis revealed that xanthohumol increased mRNA expression of abcg8 and cyp7a1. In addition, protein expressions of liver X receptor α and bile pump export protein were increased in the liver by xanthohumol administration when compared with the control, implying that it stimulated bile acid synthesis and cholesterol excretion to feces. In conclusion, our data demonstrate that xanthohumol improves RCT in vivo through cholesterol efflux from macrophages and excretion to feces, leading to antiatherosclerosis effects. It remains to be elucidated whether enhancement of RCT by xanthohumol could prove valuable in humans.


Asunto(s)
Anticolesterolemiantes/uso terapéutico , Colesterol/metabolismo , Suplementos Dietéticos , Flavonoides/uso terapéutico , Fármacos Gastrointestinales/uso terapéutico , Hipercolesterolemia/prevención & control , Macrófagos/metabolismo , Propiofenonas/uso terapéutico , Transportador de Casete de Unión a ATP, Subfamilia G, Miembro 8/genética , Transportador de Casete de Unión a ATP, Subfamilia G, Miembro 8/metabolismo , Animales , Aterosclerosis/etiología , Aterosclerosis/prevención & control , Transporte Biológico , Colesterol/sangre , Colesterol 7-alfa-Hidroxilasa/metabolismo , Proteínas de Transferencia de Ésteres de Colesterol/metabolismo , Dieta Alta en Grasa/efectos adversos , Heces/química , Regulación del Desarrollo de la Expresión Génica , Hipercolesterolemia/inmunología , Hipercolesterolemia/metabolismo , Hipercolesterolemia/fisiopatología , Eliminación Intestinal , Lipoproteínas HDL/sangre , Lipoproteínas HDL/metabolismo , Hígado/enzimología , Hígado/inmunología , Hígado/metabolismo , Macrófagos/inmunología , Masculino , Mesocricetus , Fosfatidilcolina-Esterol O-Aciltransferasa/sangre , Fosfatidilcolina-Esterol O-Aciltransferasa/metabolismo
8.
Br J Nutr ; 116(8): 1369-1382, 2016 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-27724985

RESUMEN

Oats are a rich source of ß-glucan, a viscous, soluble fibre recognised for its cholesterol-lowering properties, and are associated with reduced risk of CVD. Our objective was to conduct a systematic review and meta-analysis of randomised-controlled trials (RCT) investigating the cholesterol-lowering potential of oat ß-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for the risk reduction of CVD. MEDLINE, Embase, CINAHL and Cochrane CENTRAL were searched. We included RCT of ≥3 weeks of follow-up, assessing the effect of diets enriched with oat ß-glucan compared with controlled diets on LDL-cholesterol, non-HDL-cholesterol or apoB. Two independent reviewers extracted data and assessed study quality and risk of bias. Data were pooled using the generic inverse-variance method with random effects models and expressed as mean differences with 95 % CI. Heterogeneity was assessed by the Cochran's Q statistic and quantified by the I 2-statistic. In total, fifty-eight trials (n 3974) were included. A median dose of 3·5 g/d of oat ß-glucan significantly lowered LDL-cholesterol (-0·19; 95 % CI -0·23, -0·14 mmol/l, P<0·00001), non-HDL-cholesterol (-0·20; 95 % CI -0·26, -0·15 mmol/l, P<0·00001) and apoB (-0·03; 95 % CI -0·05, -0·02 g/l, P<0·0001) compared with control interventions. There was evidence for considerable unexplained heterogeneity in the analysis of LDL-cholesterol (I 2=79 %) and non-HDL-cholesterol (I 2=99 %). Pooled analyses showed that oat ß-glucan has a lowering effect on LDL-cholesterol, non-HDL-cholesterol and apoB. Inclusion of oat-containing foods may be a strategy for achieving targets in CVD reduction.


Asunto(s)
Anticolesterolemiantes/uso terapéutico , Avena/química , Enfermedades Cardiovasculares/prevención & control , Suplementos Dietéticos , Medicina Basada en la Evidencia , Hipercolesterolemia/dietoterapia , beta-Glucanos/uso terapéutico , Anticolesterolemiantes/administración & dosificación , Anticolesterolemiantes/química , Apolipoproteínas B/antagonistas & inhibidores , Apolipoproteínas B/sangre , Biomarcadores/sangre , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/etiología , Colesterol/sangre , Colesterol/química , HDL-Colesterol/agonistas , HDL-Colesterol/sangre , LDL-Colesterol/antagonistas & inhibidores , LDL-Colesterol/sangre , Fibras de la Dieta/administración & dosificación , Fibras de la Dieta/uso terapéutico , Alimentos Funcionales , Humanos , Hipercolesterolemia/sangre , Hipercolesterolemia/fisiopatología , Persona de Mediana Edad , Ensayos Clínicos Controlados Aleatorios como Asunto , Riesgo , Semillas/química , Solubilidad , beta-Glucanos/administración & dosificación , beta-Glucanos/química
9.
Am J Clin Nutr ; 104(3): 827-36, 2016 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-27510539

RESUMEN

BACKGROUND: The apolipoprotein E (APOE) risk allele (ɛ4) is associated with higher total cholesterol (TC), amplified response to saturated fatty acid (SFA) reduction, and increased cardiovascular disease. Although knowledge of gene risk may enhance dietary change, it is unclear whether ɛ4 carriers would benefit from gene-based personalized nutrition (PN). OBJECTIVES: The aims of this study were to 1) investigate interactions between APOE genotype and habitual dietary fat intake and modulations of fat intake on metabolic outcomes; 2) determine whether gene-based PN results in greater dietary change than do standard dietary advice (level 0) and nongene-based PN (levels 1-2); and 3) assess the impact of knowledge of APOE risk (risk: E4+, nonrisk: E4-) on dietary change after gene-based PN (level 3). DESIGN: Individuals (n = 1466) recruited into the Food4Me pan-European PN dietary intervention study were randomly assigned to 4 treatment arms and genotyped for APOE (rs429358 and rs7412). Diet and dried blood spot TC and ω-3 (n-3) index were determined at baseline and after a 6-mo intervention. Data were analyzed with the use of adjusted general linear models. RESULTS: Significantly higher TC concentrations were observed in E4+ participants than in E4- (P < 0.05). Although there were no significant differences in APOE response to gene-based PN (E4+ compared with E4-), both groups had a greater reduction in SFA (percentage of total energy) intake than at level 0 (mean ± SD: E4+, -0.72% ± 0.35% compared with -1.95% ± 0.45%, P = 0.035; E4-, -0.31% ± 0.20% compared with -1.68% ± 0.35%, P = 0.029). Gene-based PN was associated with a smaller reduction in SFA intake than in nongene-based PN (level 2) for E4- participants (-1.68% ± 0.35% compared with -2.56% ± 0.27%, P = 0.025). CONCLUSIONS: The APOE ɛ4 allele was associated with higher TC. Although gene-based PN targeted to APOE was more effective in reducing SFA intake than standard dietary advice, there was no difference between APOE "risk" and "nonrisk" groups. Furthermore, disclosure of APOE nonrisk may have weakened dietary response to PN. This trial was registered at clinicaltrials.gov as NCT01530139.


Asunto(s)
Apolipoproteína E4/genética , Dieta con Restricción de Grasas , Hipercolesterolemia/genética , Cooperación del Paciente , Educación del Paciente como Asunto , Polimorfismo de Nucleótido Simple , Medicina de Precisión , Adulto , Alelos , Apolipoproteína E4/metabolismo , Enfermedades Cardiovasculares/sangre , Enfermedades Cardiovasculares/etiología , Enfermedades Cardiovasculares/genética , Enfermedades Cardiovasculares/prevención & control , Colesterol/sangre , Estudios de Cohortes , Correo Electrónico , Europa (Continente) , Ácidos Grasos Omega-3/sangre , Femenino , Predisposición Genética a la Enfermedad , Humanos , Hipercolesterolemia/sangre , Hipercolesterolemia/fisiopatología , Hipercolesterolemia/prevención & control , Internet , Masculino , Nutrigenómica/métodos , Pacientes Desistentes del Tratamiento , Servicios Postales
10.
Ann Nutr Metab ; 68(3): 213-9, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27055107

RESUMEN

AIM: The aim of our study was to investigate whether treatment with red yeast rice added with Coenzyme Q10 is associated with changes in endothelial function and arterial stiffness. METHODS: This double blind, placebo-controlled, randomized clinical trial was carried out on 40 non-smoker moderately hypercholesterolemic subjects (ClinicalTrial.gov ID NCT02492464). After 4 weeks of diet and physical activity, patients were allocated to treatment with placebo or with an active product containing 10 mg monacolins and 30 mg Coenzyme Q10, to be assumed for 6 months. Endothelial reactivity and arterial stiffness have been measured through the validated Vicorder® device. RESULTS: During monacolin treatment, patients experienced a more favorable percentage change in low density lipoprotein (LDL)-cholesterol (after monacolin treatment: -26.3%; after placebo treatment: +3.4%, p < 0.05). Endothelial reactivity (pulse volume displacement after monacolin treatment: +6.0%; after placebo treatment: -0.3%, p < 0.05), and arterial stiffness (pulse wave velocity (PWV) after monacolin treatment: -4.7%; after placebo: +1.1%, p < 0.05) also significantly improved only after monacolin treatment. CONCLUSION: The long-term assumption of the tested dietary supplement is associated with an improvement in LDL-cholesterolemia, endothelial reactivity and PWV in moderately hypercholesterolemic subjects.


Asunto(s)
Anticolesterolemiantes/uso terapéutico , Productos Biológicos/uso terapéutico , Suplementos Dietéticos , Endotelio Vascular/fisiopatología , Hipercolesterolemia/dietoterapia , Ubiquinona/análogos & derivados , Enfermedades Vasculares/prevención & control , LDL-Colesterol/sangre , Terapia Combinada , Dieta Mediterránea , Método Doble Ciego , Ejercicio Físico , Femenino , Humanos , Hipercolesterolemia/sangre , Hipercolesterolemia/fisiopatología , Hipercolesterolemia/terapia , Italia , Masculino , Persona de Mediana Edad , Monascus/química , Naftalenos/uso terapéutico , Índice de Severidad de la Enfermedad , Ubiquinona/uso terapéutico , Enfermedades Vasculares/etiología , Resistencia Vascular , Rigidez Vascular
11.
Am J Clin Nutr ; 103(1): 25-38, 2016 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-26607938

RESUMEN

BACKGROUND: The beneficial cardiovascular effects of vegetables may be underpinned by their high inorganic nitrate content. OBJECTIVE: We sought to examine the effects of a 6-wk once-daily intake of dietary nitrate (nitrate-rich beetroot juice) compared with placebo intake (nitrate-depleted beetroot juice) on vascular and platelet function in untreated hypercholesterolemics. DESIGN: A total of 69 subjects were recruited in this randomized, double-blind, placebo-controlled parallel study. The primary endpoint was the change in vascular function determined with the use of ultrasound flow-mediated dilatation (FMD). RESULTS: Baseline characteristics were similar between the groups, with primary outcome data available for 67 patients. Dietary nitrate resulted in an absolute increase in the FMD response of 1.1% (an ∼24% improvement from baseline) with a worsening of 0.3% in the placebo group (P < 0.001). A small improvement in the aortic pulse wave velocity (i.e., a decrease of 0.22 m/s; 95% CI: -0.4, -0.3 m/s) was evident in the nitrate group, showing a trend (P = 0.06) to improvement in comparison with the placebo group. Dietary nitrate also caused a small but significant reduction (7.6%) in platelet-monocyte aggregates compared with an increase of 10.1% in the placebo group (P = 0.004), with statistically significant reductions in stimulated (ex vivo) P-selectin expression compared with the placebo group (P < 0.05) but no significant changes in unstimulated expression. No adverse effects of dietary nitrate were detected. The composition of the salivary microbiome was altered after the nitrate treatment but not after the placebo treatment (P < 0.01). The proportions of 78 bacterial taxa were different after the nitrate treatment; of those taxa present, 2 taxa were responsible for >1% of this change, with the proportions of Rothia mucilaginosa trending to increase and Neisseria flavescens (P < 0.01) increased after nitrate treatment relative to after placebo treatment. CONCLUSIONS: Sustained dietary nitrate ingestion improves vascular function in hypercholesterolemic patients. These changes are associated with alterations in the oral microbiome and, in particular, nitrate-reducing genera. Our findings provide additional support for the assessment of the potential of dietary nitrate as a preventative strategy against atherogenesis in larger cohorts. This trial was registered at clinicaltrials.gov as NCT01493752.


Asunto(s)
Beta vulgaris/química , Dieta , Hipercolesterolemia , Nitratos/farmacología , Vasodilatación/efectos de los fármacos , Verduras/química , Adulto , Aterosclerosis/sangre , Aterosclerosis/prevención & control , Bacterias/metabolismo , Plaquetas/metabolismo , Método Doble Ciego , Femenino , Humanos , Hipercolesterolemia/sangre , Hipercolesterolemia/tratamiento farmacológico , Hipercolesterolemia/fisiopatología , Masculino , Persona de Mediana Edad , Monocitos/metabolismo , Mucosa Bucal/microbiología , Nitratos/uso terapéutico , Nitritos/metabolismo , Selectina-P/sangre , Saliva/microbiología
12.
Am J Clin Nutr ; 102(6): 1339-46, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26561632

RESUMEN

BACKGROUND: Adverse effects of industrially produced trans fatty acids (iTFAs) on the risk of coronary artery disease are well documented in the scientific literature; however, effects of naturally occurring trans fatty acids (TFAs) from ruminant animals (rTFA), such as vaccenic acid (VA) and cis-9,trans-11 conjugated linoleic acid (c9,t11-CLA), are less clear. Although animal and cell studies suggest that VA and c9,t11-CLA may be hypocholesterolemic and antiatherogenic, epidemiologic data comparing rTFAs and iTFAs are inconsistent, and human intervention studies have been limited, underpowered, and not well controlled. OBJECTIVE: We determined the effects of VA, c9,t11-CLA, and iTFA, in the context of highly controlled diets (24 d each), on lipoprotein risk factors compared with a control diet. RESULTS: We conducted a double-blind, randomized, crossover feeding trial in 106 healthy adults [mean ± SD age: 47 ± 10.8 y; body mass index (in kg/m(2)): 28.5 ± 4.0; low-density lipoprotein (LDL) cholesterol: 3.24 ± 0.63 mmol/L]. Diets were designed to have stearic acid replaced with the following TFA isomers (percentage of energy): 0.1% mixed isomers of TFA (control), ∼3% VA, ∼3% iTFA, or 1% c9,t11-CLA. Total dietary fat (34% of energy) and other macronutrients were matched. Total cholesterol (TC), LDL cholesterol, triacylglycerol, lipoprotein(a), and apolipoprotein B were higher after VA than after iTFA; high-density lipoprotein (HDL) cholesterol and apolipoprotein AI also were higher after VA. Compared with control, VA and iTFA both increased TC, LDL cholesterol, ratio of TC to HDL cholesterol, and apolipoprotein B (2-6% change; P < 0.05); VA also increased HDL cholesterol, apolipoprotein AI, apolipoprotein B, and lipoprotein(a) (2-6% change; P < 0.05), whereas iTFA did not. c9,t11-CLA lowered triacylglycerol (P ≤ 0.01) and had no effect on other lipoprotein risk factors. CONCLUSIONS: With respect to risk of cardiovascular disease, these results are consistent with current nutrition labeling guidelines, with the requirement of VA, but not c9,t11-CLA, to be listed under TFA on the Nutrition Facts Panel. This trial was registered at clinicaltrials.gov as NCT00942656.


Asunto(s)
LDL-Colesterol/agonistas , Grasas Insaturadas en la Dieta/efectos adversos , Hipercolesterolemia/etiología , Ácidos Linoleicos Conjugados/efectos adversos , Ácidos Oléicos/efectos adversos , Aceites de Plantas/efectos adversos , Ácidos Grasos trans/efectos adversos , Adulto , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/etiología , Colesterol/agonistas , Colesterol/sangre , LDL-Colesterol/sangre , Estudios Cruzados , Método Doble Ciego , Femenino , Humanos , Hidrogenación , Hipercolesterolemia/sangre , Hipercolesterolemia/fisiopatología , Hipertrigliceridemia/sangre , Hipertrigliceridemia/etiología , Hipertrigliceridemia/fisiopatología , Masculino , Persona de Mediana Edad , Aceites de Plantas/química , Factores de Riesgo , Triglicéridos/agonistas , Triglicéridos/sangre
13.
Lik Sprava ; (1-2): 3-9, 2015.
Artículo en Ruso | MEDLINE | ID: mdl-26118019

RESUMEN

The review is devoted to the issues of using smectites in medicine. Modern information concerning smectite composition, structure, physico-chemical properties and reasonability of using them with health-improving purposes is presented. Special attention is given to smectite sorbtional and ionic properties and their unique mineral composition. Characterization is given to modern preparation based on smectites, including developed in Ukraine dietary additives of the series Smectovit®.


Asunto(s)
Colitis/dietoterapia , Suplementos Dietéticos , Fármacos Gastrointestinales/uso terapéutico , Silicatos/uso terapéutico , Enfermedades Cardiovasculares/dietoterapia , Enfermedades Cardiovasculares/fisiopatología , Colitis/fisiopatología , Fármacos Gastrointestinales/química , Humanos , Hipercolesterolemia/dietoterapia , Hipercolesterolemia/fisiopatología , Hipoglucemia/dietoterapia , Hipoglucemia/fisiopatología , Convulsiones/dietoterapia , Convulsiones/fisiopatología , Silicatos/química , Desintoxicación por Sorción/métodos , Ucrania
14.
Int J Food Sci Nutr ; 66(4): 400-8, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25830945

RESUMEN

The effects of replacing dietary saturated fat by different monounsaturated fatty acid (ω-9MUFA) sources on serum lipids, body fat and bone in growing hypercholesterolemic rats were studied. Rats received one of the six different diets: AIN-93G (control, C); extra virgin olive oil (OO) + C; high-oleic sunflower oil (HOSO) + C or atherogenic diet (AT) for 8 weeks; the remaining two groups received AT for 3 weeks and then, the saturated fat was replaced by an oil mixture of soybean oil added with OO or HOSO for 5 weeks. Rats consuming MUFA-rich diets showed the highest body fat, hepatic index and epididymal, intestinal and perirenal fat, and triglycerides. T-chol and non-HDL-chol were increased in HOSO rats but decreased in OO rats. Bone mineral content and density were higher in both OO and HOSO groups than in AT rats. This study casts caution to the generalization of the benefits of MUFA for the treatment of hypercholesterolemia.


Asunto(s)
Dieta/métodos , Ácidos Grasos Monoinsaturados/farmacología , Hipercolesterolemia/sangre , Hipercolesterolemia/fisiopatología , Tejido Adiposo/fisiología , Animales , Densidad Ósea/fisiología , Dieta/estadística & datos numéricos , Dieta Aterogénica , Modelos Animales de Enfermedad , Ácidos Grasos Monoinsaturados/sangre , Lípidos/sangre , Hígado/fisiopatología , Masculino , Aceite de Oliva/administración & dosificación , Aceites de Plantas/administración & dosificación , Ratas , Ratas Wistar , Aceite de Soja/administración & dosificación , Aceite de Girasol , Triglicéridos/sangre
15.
Food Funct ; 6(3): 963-71, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25662939

RESUMEN

Corinthian currants are a rich source of phenolic compounds, which are known to exert beneficial effects on cardiovascular disease. The hypothesis tested is whether dietary supplementation with currants attenuates atherosclerosis and affects plasma phenolics during prolonged hypercholesterolemia in rabbits. Thirty New Zealand White rabbits were fed one of four diets (normal and supplemented with 10% currants, with 0.5% cholesterol, and with 0.5% cholesterol plus 10% currants) for eight weeks. Plasma lipids, glucose and hepatic enzymes were determined. Individual phenolic compounds were identified and quantified in plasma during the dietary intervention. At the end of the study, histological examinations of aorta and liver were performed. The high-cholesterol diet resulted in hypercholesterolemia and oxidative stress, increased aspartate aminotransferase (AST) activity and induced aortic and hepatic lesion formation. Corinthian currant supplementation attenuated atherosclerotic lesions, maintained AST within the normal range and reduced oxidative stress without affecting glucose concentrations. The p-OH-benzoic and p-OH-phenylacetic acids predominated at high concentrations in plasma and remained almost constant during the study in the group that received the normal rabbit chow and the groups given food with added cholesterol either alone or supplemented with currants. Currant supplementation to the normal diet resulted in the reduced absorption of phenolic compounds, as revealed by the measurement of their plasma metabolites, suggesting a regulatory mechanism at the gut level under normal conditions.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Antioxidantes/uso terapéutico , Aterosclerosis/prevención & control , Suplementos Dietéticos , Extracto de Semillas de Uva/uso terapéutico , Hipercolesterolemia/dietoterapia , Fenoles/sangre , Animales , Antiinflamatorios no Esteroideos/efectos adversos , Antioxidantes/efectos adversos , Aorta/inmunología , Aorta/patología , Aterosclerosis/etiología , Colesterol en la Dieta/efectos adversos , Suplementos Dietéticos/efectos adversos , Endotelio Vascular/inmunología , Endotelio Vascular/patología , Frutas/química , Frutas/crecimiento & desarrollo , Alimentos Funcionales/análisis , Fármacos Gastrointestinales/efectos adversos , Fármacos Gastrointestinales/uso terapéutico , Extracto de Semillas de Uva/efectos adversos , Grecia , Hipercolesterolemia/inmunología , Hipercolesterolemia/metabolismo , Hipercolesterolemia/fisiopatología , Hígado/inmunología , Hígado/patología , Masculino , Estrés Oxidativo , Fenoles/antagonistas & inhibidores , Fenoles/metabolismo , Conejos , Distribución Aleatoria , Vitis/química , Vitis/crecimiento & desarrollo
16.
Exp Gerontol ; 62: 53-62, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25572014

RESUMEN

Leaves of Ficus glumosa are used in northern Cameroon and southern Chad for the treatment of cardiovascular diseases, as food and as a stimulant for milk production in both women and animals. Atherosclerosis is a disease in which frequency increases with age. The first lesions appear at the young subject during adolescence. Atherosclerosis lesions appear very precociously and worsen with age. They interest the levels chronologically aortic, coronary then carotid. Age is a risk factor in that it reflects the exposure time of individual to the other risk factors. The frequency of the atherosclerosis increases with age because of the aging of the cells. This study was undertaken to evaluate the hypolipidemic and anti-atherosclerotic properties of aqueous extract of the leaves of F. glumosa in rats with hypercholesterolemia (HC). 60 male rats were fed for 4 weeks with a high-cholesterol diet (1%) and 3 doses (225, 300 and 375 mg/kg) of extract of F. glumosa were used in these experiments. The experiments were conducted under the same conditions with atorvastatin (1 mg/kg), as pharmacological reference substance. The effects of F. glumosa on weight gain, water and food consumption, levels of serum lipids and lipoprotein lipid oxidation and stress markers in the blood and liver were examined. The administration of F. glumosa extract prevented significant (P<0.05) elevation in TC, LDL-c, VLDL-c, hepatic and aortic TG and TC. The atherogenic, triglyceride, and lipid peroxidation (TBARS) indexes were also decreased in the rats treated with the extract. F. glumosa favored the performance of fecal cholesterol. It also significantly inhibited the changes and the formation of aortic atherosclerotic plaques. These results revealed the hypolipidemic and antiatherosclerotic effects of F. glumosa extract and support the traditional use of the extract of this plant in the treatment of hypertension and diabetes.


Asunto(s)
Aterosclerosis/prevención & control , Ficus , Hipercolesterolemia/prevención & control , Hipolipemiantes/uso terapéutico , Fitoterapia/métodos , Animales , Aterosclerosis/fisiopatología , Peso Corporal/efectos de los fármacos , Ingestión de Líquidos/efectos de los fármacos , Evaluación Preclínica de Medicamentos/métodos , Ingestión de Alimentos/efectos de los fármacos , Ficus/química , Hipercolesterolemia/fisiopatología , Hipolipemiantes/farmacología , Lípidos/sangre , Masculino , Extractos Vegetales/química , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico , Hojas de la Planta/química , Ratas Wistar
17.
J Diet Suppl ; 12(2): 173-83, 2015 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-25167076

RESUMEN

BACKGROUND: We reported that Jamaican bitter yam (Dioscorea polygonoides) has antilipemic potential in rats; however there is limited data on the toxicological profile of the yam. We therefore investigated the effects of bitter yam consumption for 6 or 12 weeks on renal and hepatic function in rats fed a high (4%) cholesterol diet. METHODS: Twenty four rats were divided into six groups (n = 4); three of which were used for each investigation (6 or 12 weeks). One group was administered 4% cholesterol diet, while the yam group had the cholesterol diet supplemented with 5% bitter yam. The control group was fed standard rat chow. Liver and kidney function tests were performed on serum, liver and kidney. Histological studies were conducted on liver samples. Acute toxicity tests were performed in rats and mice administered a single high dose of bitter yam (10 g/kg). RESULTS: Activities of liver and kidney AST and ALT differed (p ≤ .02) between control rats and those fed cholesterol with bitter yam for 12 weeks. Albumin to globulin ratio was reduced (p = .03) in rats fed cholesterol with bitter yam for 6 weeks as compared to the control group. Serum urea concentration was higher (p < .05) in rats fed bitter yam as compared to normal chow for 6 weeks. The cholesterol diet caused extensive fat deposition in liver cells; however this was inhibited by co-administration of bitter yam. CONCLUSION: Long-term administration of Jamaican bitter yam may induce slight changes in renal and hepatic functions.


Asunto(s)
Anticolesterolemiantes/administración & dosificación , Dioscorea/toxicidad , Hipercolesterolemia/tratamiento farmacológico , Hipercolesterolemia/fisiopatología , Riñón/fisiopatología , Hígado/fisiopatología , Animales , Colesterol en la Dieta/administración & dosificación , Dieta , Dioscorea/química , Riñón/efectos de los fármacos , Hígado/efectos de los fármacos , Hígado/patología , Fitoterapia , Tubérculos de la Planta/química , Ratas , Ratas Sprague-Dawley
19.
J Med Food ; 17(8): 921-8, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24650072

RESUMEN

There is a general assumption that seaweeds are hypocholesterolemics and antioxidants. However, controversial results suggest specific properties for each individual alga. This study aims to assess the effect of including Sea Spaghetti alga (S) in a restructured-pork (RP) diet, both enriched and not enriched with dietary cholesterol, on arylesterase (AE) activity and lipoprotein concentration and composition of Wistar rats. Four groups of 10 growing male Wistar rats were each fed a mix of 85% AIN-93M diet and 15% freeze-dried RP for 5 weeks. The control group (C) consumed control RP-C; the S group consumed RP-S with 5% seaweeds; the Chol-C group consumed the C diet but enriched with cholesterol (2.43%) and cholic acid (0.49%); the Chol-S group consumed the S diet but enriched with cholesterol and cholic acid. AE activity was five times higher (P<.01) in S compared with C rats, but three times lower in Chol-S compared with Chol-C rats (P<.01). The Chol-C diet induced hypercholesterolemia but reduced triglycerides (TG), giving rise to the presence of very low-density lipoprotein (VLDL) that was enriched in cholesterol. The Chol-S diet partially blocked (P<.001) the hypercholesterolemic induction of the Chol-C diet, and reduced TG levels (P<.05) with respect to S rats. The cholesterol supplementation increased total cholesterol, VLDL-cholesterol, and intermediate-density lipoprotein+LDL-cholesterol (IDL+LDL)-cholesterol (P<.001) in Chol-C rats, but the effect was lower in the Chol-S diet. In conclusion, RP-S increases the antioxidant capacity within a noncholesterol enriched diet while improving the lipoprotein profile within a cholesterol-enriched diet.


Asunto(s)
Hidrolasas de Éster Carboxílico/metabolismo , Colesterol en la Dieta/metabolismo , Enfermedad Coronaria/dietoterapia , Hipercolesterolemia/dietoterapia , Lipoproteínas/metabolismo , Productos de la Carne/análisis , Phaeophyceae/metabolismo , Algas Marinas/metabolismo , Animales , Enfermedad Coronaria/metabolismo , Enfermedad Coronaria/fisiopatología , Aditivos Alimentarios/metabolismo , Manipulación de Alimentos , Humanos , Hipercolesterolemia/metabolismo , Hipercolesterolemia/fisiopatología , Hipercolesterolemia/prevención & control , Masculino , Ratas , Ratas Wistar , Porcinos
20.
J Med Food ; 17(5): 612-7, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24476220

RESUMEN

Cardiovascular disease (CVD) is the leading cause of death in the world and is the primary cause of mortality among Americans. One of the many reasons for the pathogenesis of CVD is attributed to eating diets high in saturated fat and refined carbohydrates and low in fruits and vegetables. Epidemiological evidence has supported a strong association between eating diets rich in fruits and vegetables and cardiovascular health. An experiment was conducted utilizing 24 adults with hypercholesterolemia and hypertriglyceridemia to evaluate the impact of drinking 20 fl oz of freshly squeezed orange juice daily for 90 days on blood pressure, lipid panels, plasma antioxidant capacity, metabolic hormones, lipid peroxidation, and inflammatory markers. Except for addition of drinking orange juice, subjects did not modify their eating habits. The findings suggested that drinking orange juice does not affect (P>.1) blood pressure, lipid panels, metabolic hormones, body fat percentage, or inflammatory markers. However, total plasma antioxidant capacity was significantly increased (P<.05) and lipid peroxidation was significantly decreased (P<.05) after orange juice consumption. Drinking orange juice may protect the cardiovascular system by increasing total plasma antioxidant status and by lowering lipid peroxidation independent of other cardiovascular risk markers evaluated in this study.


Asunto(s)
Antioxidantes/análisis , Bebidas , Enfermedades Cardiovasculares/prevención & control , Citrus sinensis , Frutas , Peroxidación de Lípido , Biomarcadores/sangre , Presión Sanguínea , Dieta , Femenino , Frutas/química , Humanos , Hipercolesterolemia/sangre , Hipercolesterolemia/fisiopatología , Hipertrigliceridemia/sangre , Hipertrigliceridemia/fisiopatología , Inflamación/sangre , Lípidos/sangre , Masculino , Persona de Mediana Edad , Factores Sexuales
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA